BREAST CANCER

Dr. Tarantino discuss the integration of recent trial data into post-neoadjuvant treatment strategies, comparing adjuvant T-DM1 with pertuzumab plus trastuzumab.

Dr. Tarantino summarize the trial's design comparing adjuvant T-DM1 versus trastuzumab for residual invasive disease post-neoadjuvant therapy. Discussions include efficacy comparisons, recent 5-year OS analysis results, and the significant IDFS benefits observed with T-DM1 over an 8+ year follow-up period.

Dr. Tarantino discuss long-term safety and efficacy findings from the APHINITY trial's 8-year follow-up with pertuzumab, and insights from the NeoSphere study's impact on treatment strategies based on efficacy and safety data.

Paolo Tarantino, MD, discusses risk factors in early breast cancer, NCCN guideline-recommended therapies, and the transformative impact of HER2-targeted treatments over the past decade.

Erin E. Hahn, PhD, MPH, discussed the findings and implications of a retrospective study exploring breast cancer surveillance in pre- and post-COVID periods.

Pierfranco Conte, MD, discusses findings and implications of the A-BRAVE study.

A study suggests a PIK3CA mutation and blood tests before and after treatment may predict response to alisertib in HR+/HER2–metastatic breast cancer.

Mridula George, MD, discussed a study investigating ctDNA monitoring during neoadjuvant therapy of breast cancer.

Patients treated with hormone-modulating therapy for breast cancer had a reduced risk of developing Alzheimer disease or dementia compared with patients treated with other agents.

During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.

During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.

Laura Huppert, MD, discussed a retrospective study exploring the sequential use of antibody-drug conjugates for the treatment of HER2-low metastatic breast cancer.

During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.

Erika Hamilton, MD, discussed findings from the phase 1b/2 ELECTRA study investigating a new oral combination therapy for patients with metastatic breast cancer.

Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, provide closing thoughts on the evolving treatment landscape for HER-negative and HER2-low metastatic breast cancer.

A phase 1 trial is underway to assess the safety and efficacy of BTX-9341, a novel investigational oral degrader of CDK4/6 in HR-positive/HER2-negative breast cancer.

In a live virtual event, Aditya Bardia, MD, MPH, discussed the treatment landscape for patients with advanced invasive breast cancer.

Denise Yardley, MD, discusses the takeaways and next steps of an analysis of the NATALEE trial investigating ribociclib in node-negative breast cancer.

In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.

Medical oncologists share clinical practices for selecting and sequencing TROP2-directed antibody-drug conjugates, highlighting ideal candidates for sacituzumab govitecan or datopotamab deruxtecan.

Experts on breast cancer offer comprehensive insights on findings from the TROPiCS-02 study investigating sacituzumab govitecan in patients with HR+/HER2- metastatic or locally recurrent inoperable breast cancer.

Breast cancer specialists review the study design, efficacy data, and safety profile findings from the TROPION-Breast01 study investigating datopotamab deruxtecan (Dato-DXd) in patients with HR+/HER2- metastatic breast cancer.

Medical oncologists provide insights on emerging pathways and TROP2-directed antibody-drug conjugates in HR+/HER2- metastatic breast cancer, highlighting ongoing research.

Hope S. Rugo, MD, discusses the ELEVATE trial of elacestrant combined with various targeted therapies for patients with endocrine receptor-positive/HER2-negative metastatic breast cancer who have already received endocrine therapy and CDK4/6 inhibitors.

Tanya Gupta, MD, discusses the current landscape of antibody-drug conjugates for breast cancer subtypes beyond HER2-positive disease.